China's National Medical Products Administration has granted expanded approval to MSD's GARDASIL for use in males aged nine to 26 years.

Araris will use its linker technology to generate multi-warhead ADCs for “undisclosed targets” provided by Chugai.

Orna will receive a $65m upfront payment and is eligible to receive potential milestone payments and royalties.

GSK has gained US FDA breakthrough therapy designation for GSK'227 to treat adults with relapsed or refractory osteosarcoma.

Acelyrin plans to initiate two Phase III studies this quarter, which will enrol up to 350 patients with thyroid eye disease (TED).

Variant has entered a multi-year research partnership with Novo Nordisk to identify new targets to treat metabolic conditions.

The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

The FDA has accepted for filing and priority review Sentynl Therapeutics’ CUTX-101 NDA for the treatment of Menkes disease.

The FDA has granted ODD to Tempest's amezalpat (TPST-1120), for individuals with hepatocellular carcinoma (HCC).

The landscape of pandemic response has been transformed, with new standards being set for clinical excellence. A new report looks at emerging therapies, trial insights, and the innovations shaping the ...

Explore how strategic intelligence agencies and competitive intelligence solutions are shaping the pharmaceutical industry. Download our guide to technological advancements and more invaluable ...

Orbis Medicines has raised €90m ($94m) in Series A funding to advance the development of its next-generation orally dosable macrocycle drugs.